[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG10201707518YA - Human antibodies to grem 1 - Google Patents

Human antibodies to grem 1

Info

Publication number
SG10201707518YA
SG10201707518YA SG10201707518YA SG10201707518YA SG10201707518YA SG 10201707518Y A SG10201707518Y A SG 10201707518YA SG 10201707518Y A SG10201707518Y A SG 10201707518YA SG 10201707518Y A SG10201707518Y A SG 10201707518YA SG 10201707518Y A SG10201707518Y A SG 10201707518YA
Authority
SG
Singapore
Prior art keywords
grem
human antibodies
antibodies
human
Prior art date
Application number
SG10201707518YA
Other languages
English (en)
Inventor
Aris Economides
Vincent J Idone
Lori C Morton
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201707518YA publication Critical patent/SG10201707518YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201707518YA 2013-03-14 2014-03-07 Human antibodies to grem 1 SG10201707518YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782874P 2013-03-14 2013-03-14
US201361883218P 2013-09-27 2013-09-27

Publications (1)

Publication Number Publication Date
SG10201707518YA true SG10201707518YA (en) 2017-10-30

Family

ID=50390267

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201506459PA SG11201506459PA (en) 2013-03-14 2014-03-07 Human antibodies to grem 1
SG10201707518YA SG10201707518YA (en) 2013-03-14 2014-03-07 Human antibodies to grem 1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201506459PA SG11201506459PA (en) 2013-03-14 2014-03-07 Human antibodies to grem 1

Country Status (18)

Country Link
US (3) US10377817B2 (ja)
EP (1) EP2970448B1 (ja)
JP (2) JP6581075B2 (ja)
KR (1) KR20150129718A (ja)
CN (1) CN105189548A (ja)
AU (1) AU2014241442B2 (ja)
BR (1) BR112015021979A2 (ja)
CA (1) CA2904644C (ja)
CL (1) CL2015002603A1 (ja)
EA (1) EA201591762A1 (ja)
ES (1) ES2898620T3 (ja)
HK (1) HK1220469A1 (ja)
IL (1) IL240769A0 (ja)
MX (1) MX369574B (ja)
PH (1) PH12015501865A1 (ja)
SG (2) SG11201506459PA (ja)
WO (1) WO2014159010A1 (ja)
ZA (1) ZA201506113B (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013137686A1 (ko) * 2012-03-15 2013-09-19 서울대학교 산학협력단 그렘린-1에 대한 항체
ES2898620T3 (es) 2013-03-14 2022-03-08 Regeneron Pharma Anticuerpos humanos contra GREM 1
US10865244B2 (en) 2016-04-18 2020-12-15 Celldex Therapeutics, Inc. Nucleic acids encoding agonistic antibodies that bind CD40
CN106399316B (zh) * 2016-08-26 2019-03-01 西安交通大学第一附属医院 用于识别Gremlin-1的核酸适配子及其应用
EP3504238A1 (en) 2016-08-29 2019-07-03 Regeneron Pharmaceuticals, Inc. Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension
CN110234348B (zh) * 2016-12-16 2024-06-25 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
GB201621635D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
MA49273A (fr) 2017-03-22 2020-02-05 Bluefin Biomedicine Inc Anticorps anti-tmeff1 et conjugués anticorps-médicament
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
MX2020013808A (es) * 2018-06-18 2021-05-27 UCB Biopharma SRL Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
WO2020106461A2 (en) * 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
WO2021102173A1 (en) * 2019-11-21 2021-05-27 Unity Biotechnology Antibodies directed to tie-2 and methods of use
EP4232475A1 (en) 2020-10-20 2023-08-30 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
TW202237642A (zh) * 2021-01-08 2022-10-01 美商１０Ｘ基因組學有限公司 對冠狀病毒具有特異性的抗原結合多肽及其用途
MX2023008423A (es) * 2021-01-18 2023-07-26 Suzhou Transcenta Therapeutics Co Ltd Anticuerpos anti-gremlin1 novedosos.
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
WO2023203177A1 (en) * 2022-04-20 2023-10-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑
WO2024213066A1 (en) * 2023-04-13 2024-10-17 Suzhou Transcenta Therapeutics Co., Ltd. Combination therapies involving grem1 antagonists for treatment of cancer
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
AU6267098A (en) 1997-02-05 1998-08-25 Regents Of The University Of California, The Morphogenic proteins
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR20100013352A (ko) 2001-10-31 2010-02-09 알콘, 인코퍼레이티드 뼈 형태발생 단백질(ｂｍｐ), ｂｍｐ 수용체 및 ｂｍｐ 결합 단백질 및 녹내장 진단 및 치료에서 그의 용도
EP1777519A1 (en) 2001-10-31 2007-04-25 Alcon, Inc. Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
JP2008531525A (ja) 2005-02-24 2008-08-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチド製剤を安定化する化合物
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
WO2007124486A2 (en) 2006-04-21 2007-11-01 Childrens Hospital Los Angeles Bmp4 inhibitors
SI2374818T1 (sl) 2006-06-02 2013-03-29 Regeneron Pharmaceuticals, Inc. Visokoafinitetna protitelesa za humani IL-6 receptor
US8383349B2 (en) * 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
JP5410434B2 (ja) 2007-09-28 2014-02-05 バインド セラピューティックス インコーポレイテッド ナノ粒子を用いた癌細胞の標的化
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
KR101835648B1 (ko) 2009-06-26 2018-03-07 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
WO2013137686A1 (ko) 2012-03-15 2013-09-19 서울대학교 산학협력단 그렘린-1에 대한 항체
ES2898620T3 (es) 2013-03-14 2022-03-08 Regeneron Pharma Anticuerpos humanos contra GREM 1

Also Published As

Publication number Publication date
JP2016519650A (ja) 2016-07-07
SG11201506459PA (en) 2015-09-29
IL240769A0 (en) 2015-10-29
EP2970448A1 (en) 2016-01-20
US10377817B2 (en) 2019-08-13
MX369574B (es) 2019-11-13
CL2015002603A1 (es) 2016-03-04
JP2019151654A (ja) 2019-09-12
US11634480B2 (en) 2023-04-25
AU2014241442B2 (en) 2018-11-15
HK1220469A1 (zh) 2017-05-05
US20200157194A1 (en) 2020-05-21
PH12015501865A1 (en) 2015-12-07
ZA201506113B (en) 2016-07-27
CA2904644C (en) 2022-09-20
MX2015011616A (es) 2015-12-17
BR112015021979A2 (pt) 2017-08-29
KR20150129718A (ko) 2015-11-20
EP2970448B1 (en) 2021-11-03
AU2014241442A1 (en) 2015-10-15
JP6581075B2 (ja) 2019-09-25
EA201591762A1 (ru) 2015-12-30
US20160024195A1 (en) 2016-01-28
CA2904644A1 (en) 2014-10-02
WO2014159010A1 (en) 2014-10-02
ES2898620T3 (es) 2022-03-08
US20230192831A1 (en) 2023-06-22
CN105189548A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
IL240769A0 (en) Human antibodies to 1 grem
HK1220468A1 (zh) 的人抗體
IL262804A (en) Antibodies to human pac1
GB2510579B (en) Zipper
HK1219961A1 (zh) 人抗α型干擾素抗體
HK1219962A1 (zh) 人抗白細胞介素- 抗體
GB201312513D0 (en) 2 4 1 Technology
EP2955226A4 (en) ANTIBODIES AGAINST HUMAN NRG1 PROTEIN
GB201322203D0 (en) Deens' merger
GB201322250D0 (en) Human targets l
GB201310748D0 (en) Student's clinic
GB201322568D0 (en) Taggstar 1
GB201313605D0 (en) Novel compounds and their use
GB201310407D0 (en) Plantladders 3
GB201310285D0 (en) Twist-Away 270
GB201311503D0 (en) Concept 38
GB201311491D0 (en) Concept 54
GB201311530D0 (en) Concept 46
GB201311529D0 (en) Concept 3
GB201311528D0 (en) Concept 44
GB201311469D0 (en) Concept 12 12
GB201311483D0 (en) Concept 48
GB201311486D0 (en) Concept 50
GB201311488D0 (en) Concept 51
GB201311489D0 (en) Concept 52